Included in the formulation
АТХ:G.04.B.C Drugs for the treatment of nephrourolythiasis
Pharmacodynamics:Dissolves and prevents the formation of uric acid stones due to alkalinization of urine to pH values of 6.6-6.8 (with urine pH in the range of 6.6-6.8, the dissolution of salts of uric acid is significantly increased). In addition, it reduces the excretion of calcium, improves the solubility of calcium oxalate in urine, inhibits the formation of crystals and, consequently, prevents the formation of calcium oxalate stones.
Pharmacokinetics:Bioavailability is about 100%. It is excreted by the kidneys.
Indications:- dissolution of uric acid and calcium oxalate stones and prevention of their formation;
- dissolution of mixed uric acid-oxalate stones (with an oxalate content of less than 25%);
- alkalinization of urine in people receiving cytotoxic drugs or drugs that increase the excretion of uric acid;
- symptomatic treatment of porphyria of the skin.
IV.E70-E90.E80.1 Porphyria cutaneous slow
XIV.N20-N23.N20 Kidney and ureter stones
XIV.N20-N23.N21 Stones of the lower parts of the urinary tract
Contraindications:hypersensitivity;
acute and chronic renal failure;
metabolic alkalosis;
- urinary tract infections caused by microorganisms that break down urea;
urine pH is higher than 7;
- the need to comply with a strict salt-free diet (for example, with severe forms of hypertension).
Contraindicated in acute and chronic renal failure. Can be used for chronic kidney failure, not accompanied by a delay of potassium ions.
Pregnancy and lactation:There is no confirmed data on the undesirable effects of the drug during pregnancy and during breastfeeding. Taking the drug is possible after consulting a doctor.
FDA recommendations are not defined.
Dosing and Administration:Inside, after eating, previously dissolved in 200 ml of liquid (tea, fruit juice or alkaline mineral water).
The daily dose is 2-6 effervescent tablets. The daily dose is evenly distributed throughout the day. The dose is considered correctly selected if the pH during the day is within the range of 6.2-7 (for dissolution of uric acid stones); 7.5-8.5 (for cystine stones); 7.2-7.5 (for the treatment of porphyria); at least 7 (in the treatment of cytostatics).If the pH value of urine is lower than indicated, the dose should be increased, if higher - reduced. Duration of treatment is 4-6 months.
Side effects:Allergic reactions, swelling (sodium retention), metabolic alkalosis, dyspepsia.
Overdose:There is no information about an overdose.
Interaction:Simultaneous administration of preparations containing citrates and aluminum can lead to increased absorption of aluminum. The interval between the methods of such drugs should be at least 2 hours. The effect of cardiac glycosides may be weakened when combined with a drug due to the presence of potassium in the formulation.
Some drugs that lower blood pressure (aldosterone antagonists, potassium-sparing diuretics, angiotensin-converting enzyme blockers), as well as anti-inflammatory non-steroid agents and analgesics can reduce the excretion of potassium.
Special instructions:The average daily dose (12 g of granular powder) contains about 1.5 mg of potassium and 0.9 g of sodium (should be taken into account in patients with a restriction of consumption of table salt).
Can be used for chronic kidney failure, not accompanied by a delay of potassium ions.
Can be prescribed to patients with diabetes mellitus.
When dissolving uric acid stones, the daily dose should not be exceeded, because with increasing pH above 7.0, phosphate precipitation occurs on the uric acid crystals, which prevents their further dissolution.
During treatment, the intake of foods rich in proteins and purine bases should be restricted, and sufficient fluid intake (at least 1.5-2 liters) should be ensured.